Association of Bariatric Surgery with Risk of Incident Obesity-Associated Malignancies: a Multi-center Population-Based Study.


Journal

Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 10 02 2023
accepted: 23 10 2023
revised: 15 10 2023
medline: 30 11 2023
pubmed: 17 11 2023
entrez: 16 11 2023
Statut: ppublish

Résumé

Obesity has a known association with certain types of malignancy, and we aimed to determine whether bariatric surgery has a protective effect against de novo obesity-associated cancer development in adult patients. We performed a multi-center retrospective cohort studying utilizing TriNetX national database. Patients were identified utilizing ICD-10-CM coding, and propensity score matching was performed. We compared patients with obesity who underwent bariatric surgery to patients with obesity who did not undergo bariatric surgery. We initially identified 60,285 patients in the bariatric surgery group and 1,570,440 patients in nonsurgical control group. After propensity score matching, we included 55,789 patients in each patient cohort. The cumulative incidence of de novo obesity-associated cancers at 10 years was 4.0% (2206 patients) in the bariatric surgery group and 8.9% (4,960 patients) in the nonsurgical control group (HR 0.482 [95% CI 0.459-0.507]). The bariatric surgery group had lower incidence proportions for de novo breast cancer (HR 0.753 [CI 0.678-0.836]), colon cancer (HR 0.638 [CI 0.541-0.752]), liver cancer (HR 0.370 [CI 0.345-0.396]), ovarian cancer (HR 0.654 [CI 0.531-0.806]), and endometrial cancer (HR 0.448 [CI 0.362-0.556]) when compared to the nonsurgical control group. We noted that bariatric surgery is associated with a significantly lower cumulative incidence of de novo obesity-associated cancer compared to a nonsurgical matched control group. Incidence proportions of de novo breast, colon, liver, ovarian, and endometrial cancer were significantly lower in adult patients with obesity in the bariatric surgery group compared to the nonsurgical group.

Identifiants

pubmed: 37971573
doi: 10.1007/s11695-023-06926-3
pii: 10.1007/s11695-023-06926-3
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4065-4069

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
doi: 10.1056/NEJMsr1606602 pubmed: 27557308 pmcid: 6754861
Arterburn DE, Telem DA, Kushner RF, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87.
doi: 10.1001/jama.2020.12567 pubmed: 32870301
Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg. 2019;269(1):95–101.
doi: 10.1097/SLA.0000000000002525 pubmed: 28938270
Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327(24):2423–33.
doi: 10.1001/jama.2022.9009 pubmed: 35657620 pmcid: 9166218
Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653–62.
doi: 10.1016/S1470-2045(09)70159-7 pubmed: 19556163
Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.
doi: 10.1097/00005650-199801000-00004 pubmed: 9431328

Auteurs

Vibhu Chittajallu (V)

Digestive Health Institute, University Hospitals, Cleveland, OH, USA.

Emad Mansoor (E)

Digestive Health Institute, University Hospitals, Cleveland, OH, USA.

Jaime Perez (J)

Digestive Health Institute, University Hospitals, Cleveland, OH, USA.

Yazan Abu Omar (YA)

Cleveland Clinic Foundation, Cleveland, OH, USA.

Stephen A Firkins (SA)

Cleveland Clinic Foundation, Cleveland, OH, USA.

Heesoo Yoo (H)

Cleveland Clinic Foundation, Cleveland, OH, USA.

Brian Baggott (B)

Cleveland Clinic Foundation, Cleveland, OH, USA.

Roberto Simons-Linares (R)

Cleveland Clinic Foundation, Cleveland, OH, USA. simonsc@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH